Does Hepatitis B Virus DNA Forecast Chronic Hepatitis in Hepatitis B Surface Antigen-positive Patients?

Abstract Introduction: Chronic hepatitis B (CHB) infection is accountable for nearly 240 million cases worldwide. Hepatitis B virus (HBV) has a propensity to show a divergent phase, and isolated measure of high HBV DNA level may not reflect the stage of the disease. In this background, this study was done to detect hepatitis B e antigen (HBeAg) and HBV DNA levels among hepatitis B surface antigen (HBsAg)-positive CHB cases and to determine the stage of disease with viral markers and biochemical parameters such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels. Materials and Methods: Blood samples were collected from 50 participants with CHB (HBsAg positive for more than 6 months) tested for HBe Ag by enzyme-linked immunosorbent assay, HBV DNA, ALT, and AST levels. Results: Among the 50 cases, 31 (62%) were HBeAg negative. Among these 31 HBeAg-negative groups, 16 (52%) had HBV DNA levels >2000 IU/mL. In these 16 patients, six had ALT >40IU/mL. Conclusion: HBsAg, HBeAg, ALT levels, and HBV DNA are important markers to determine the clinical stage of the disease. Since it is a chronic disease, patients need long-term follow-up. Further, emergence of viral mutants among vaccinated and those on lamivudine aggravates the existing problem.